

## GUIDELINE

## BSH Guideline

# A British Society for Haematology guideline on the assessment and management of bleeding risk prior to invasive procedures

Will Lester<sup>1</sup>   | Clare Bent<sup>2</sup> | Raza Alikhan<sup>3</sup>  | Lara Roberts<sup>4</sup>  |  
Tim Gordon-Walker<sup>5</sup> | Sarah Trenfield<sup>6</sup> | Richard White<sup>7</sup> |  
Colm Forde<sup>8</sup> | Deepa J. Arachchilage<sup>9,10</sup> | on behalf of the BSH Committee 

<sup>1</sup>Department of Haematology, University Hospitals Birmingham, Birmingham, UK

<sup>2</sup>Department of Radiology, University Hospitals Dorset, Dorset, UK

<sup>3</sup>Department of Haematology, University Hospitals of Cardiff, Cardiff, UK

<sup>4</sup>Department of Haematology, King College London, London, UK

<sup>5</sup>Scottish Liver Transplant Unit, Royal Infirmary of Edinburgh, Edinburgh, UK

<sup>6</sup>Department of Anaesthesia and Critical Care, Royal Brompton Hospital, London, UK

<sup>7</sup>Department of Radiology, Cardiff and Vale UHB, Cardiff, UK

<sup>8</sup>Department of Radiology, University Hospitals Birmingham, Birmingham, UK

<sup>9</sup>Department of Immunology and Inflammation, Centre for Haematology, Imperial College London, London, UK

<sup>10</sup>Department of Haematology, Imperial College Healthcare NHS Trust, London, UK

## Correspondence

Will Lester, Department of Haematology, University Hospitals Birmingham, Birmingham, UK.

Email: [will.lester@uhb.nhs.uk](mailto:will.lester@uhb.nhs.uk)

BSH Guidelines Administrator, British Society for Haematology, 100 White Lion Street, London N1 9PF, UK.

Email: [bshguidelines@b-s-h.org.uk](mailto:bshguidelines@b-s-h.org.uk)

## KEYWORDS

biopsy, bleeding risk, coagulation tests, invasive procedure, pre-operative

## METHODOLOGY

This guideline was compiled according to the British Society for Haematology (BSH) process at <https://b-s-h.org.uk/>. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) nomenclature was used to evaluate the levels of evidence and to assess the strength of recommendations. The GRADE criteria can be found at <http://www.gradeworkinggroup.org>. A literature search was carried out using the terms given in [Appendix](#).

## REVIEW OF MANUSCRIPT

Manuscript review was completed by the BSH Guidelines Haemostasis and Thrombosis Task Force, BSH Guidelines Executive Committee and the Haemostasis and Thrombosis sounding board of the BSH. Further review was performed by

the British Society of Interventional Radiology; these organisations do not necessarily approve or endorse the contents.

## INTRODUCTION

This guidance update from the BSH is focussed primarily on non-surgical invasive procedures, simply termed 'procedures' in this document, with the primary objective of giving pragmatic advice where evidence is limited. This guidance also aims to reduce unnecessary laboratory testing, inappropriate use of blood products and unnecessary delays in therapeutic procedures.<sup>1</sup> It should be read in conjunction with the Interventional Radiology (IR) procedure bleeding risk guidance produced by the British Society of Interventional Radiology (BSIR) and the BSH.<sup>2</sup> Recommendations are predominantly based on evidence from adult patients and therefore may not be applicable to neonates or very young

[Correction made on 28 March 2024 after online publication: The first name was corrected for Lara Roberts.]

© 2024 British Society for Haematology and John Wiley & Sons Ltd.


children. Figure 1 gives a recommended pathway for the pre-procedure assessment of bleeding risk.

## RECOMMENDATIONS

- Routine coagulation screening is not recommended prior to a procedure, as it does not indicate the bleeding risk nor does a normal screen exclude a bleeding disorder (1C).
- We suggest against the routine use of global haemostatic or platelet function testing to assess bleeding risk prior to a procedure (2C).
- Prior to elective procedures associated with a risk of bleeding, consider performing a structured bleeding history

including the personal and family history of spontaneous or procedure-related bleeding (e.g. HEMSTOP) (2D).

- If the bleeding history is positive, then consider referral to a haematologist for further advice (2D).
- In patients taking antiplatelet agents and/or anticoagulants who also require a procedure, it is recommended that during patient consent the balance of risks between bleeding and thromboembolism is discussed (1B).
- We suggest that a decision about continuation or cessation of dual antiplatelet therapy (DAPT), prasugrel or ticagrelor medications prior to invasive procedures should be discussed with the patient's relevant specialist for the indication prior to a procedure (2C).



\* If previous platelets <50: check within 48 hours; if previous fluctuating >50 check within 2 weeks; otherwise within 4 weeks

**FIGURE 1** Bleeding risk assessment pathway for elective nonsurgical invasive procedures. APTT, activated partial thromboplastin time; CLD, chronic liver disease; IVC, inferior vena cava; INR, international normalised ratio; MSK, musculoskeletal; PAE, prostate artery embolisation; PCNL, percutaneous nephrolithotomy; PT, prothrombin time; PTC, percutaneous transhepatic cholangiogram; SVC, superior vena cava; TACE, transarterial chemoembolisation; TIPSS, transjugular intrahepatic portosystemic shunt; UAE, uterine artery embolisation.

- Testing of the platelet count is not recommended prior to low-risk procedures (e.g. paracentesis or central line insertion), unless there is a known haematological disorder where platelet count may be  $<30 \times 10^9/L$  (1C).
- We suggest against the routine testing of prothrombin time (PT)/international normalised ratio (INR), activated partial thromboplastin time (APTT), fibrinogen and platelet count before low-risk procedures in patients with stable liver disease (e.g. therapeutic or diagnostic paracentesis) (2C).
- Consider performing a coagulation screen (PT/INR, APTT and fibrinogen) in patients undergoing a procedure with a high risk of bleeding and liver disease, malnutrition, prolonged antibiotic use and in patients with a risk of coagulopathy (e.g. *sepsis*/critical care patients) (2C).
- We recommend performing a preprocedure INR on patients on a vitamin K antagonist (VKA) (1C).
- Consider vitamin K replacement in patients with an increased INR, secondary to vitamin K deficiency, for example, cholestatic liver disease, malnutrition or prolonged antibiotic use (2D).
- Preprocedure vitamin K replacement is not recommended in individuals with cirrhosis without risk factors for vitamin K deficiency (1C).
- Routine use of fresh frozen plasma (FFP) or other replacement therapies to correct abnormal coagulation results is not recommended in patients undergoing a procedure (1C).
- We suggest against preprocedural testing of fibrinogen in non-critically ill patients (2C).
- We suggest aiming for a preprocedural fibrinogen level  $>1.0\text{ g/L}$  in critically ill patients undergoing a high-risk procedure (2C).
- The platelet count in isolation should not be used as a predictor of bleeding: The cause of thrombocytopenia, function of the platelets and patient and procedure-related risk of bleeding should be considered when deciding whether to give a prophylactic platelet transfusion (2C).
- A platelet transfusion can be considered in patients with a platelet count  $<30 \times 10^9/L$  requiring a tunnelled central venous catheter (1C).
- Thrombopoietin receptor agonists (TPO-RAs) can be considered for high-risk procedures in patients with liver disease, if the platelet count is  $<50 \times 10^9/L$  (2B).
- We suggest specialist input for patients with acute-on-chronic liver failure undergoing an essential procedure. Fibrinogen, platelet and other coagulation factor replacement can be considered on a case-by-case basis (2D).

## PROCEDURAL RISK STRATIFICATION

Published guidance ranges from stratifying procedure risk into either three tiers—low, moderate and high risk—or

a more simplified dichotomy between high and low risk. Due to differences in required haematological tests between low and moderate/high risk procedures, this guideline has used a two-tier approach for bleeding risk assessment prior to elective procedures (see [Figure 1](#)). However a three tier approach remains useful for quantifying procedural bleeding risk. Comprehensive lists of relevant procedures falling into different risk categories are provided elsewhere.<sup>3,4</sup> It has been proposed that high-risk procedures are those with a major bleeding risk of  $>1.5\%$ .<sup>5</sup> Procedures could also be considered high risk by virtue of bleeding being more difficult to diagnose and treat (e.g. retroperitoneal bleeding versus superficial soft tissue bleeding) or with more significant consequences (e.g. bleeding secondary to spinal interventions).

Procedures involving percutaneous solid organ puncture, or deep intra-abdominal drainage or biopsy, should be considered high risk. Arteriography requiring less than a 6 French sheath for access should be considered moderate risk, whereas aortoiliac or other intra-abdominal interventions such as embolisation are high risk. While the majority of venous procedures (including fistula interventions) are moderate risk, transjugular intrahepatic portosystemic shunts and thoracic venous interventions are notable exceptions and should be considered high risk.

Procedural risk will also depend on the complexity of a particular procedure. On occasion, what are generally considered low-risk procedures might be more complex than usual, for example, tunnelled central venous catheter insertion in the presence of occlusive central venous disease or attempted inferior vena cava filter retrieval in the presence of filter tilt or long implantation duration. Such procedures should be considered high risk.

## BLEEDING HISTORY

A key recommendation of the previous BSH and the more recent European Society of Anaesthesiology (ESA) guidance is the taking of a preprocedure bleeding history.<sup>1,6</sup> A 2015 survey of more than 700 members of the ESA revealed that less than half of the respondents utilised a standardised history to assess bleeding risk.<sup>7</sup> The majority of bleeding assessment tools have been developed specifically to identify subjects with an inherited bleeding disorder, most commonly von Willebrand disease (VWD).<sup>8-11</sup> Although bleeding assessment tools have also been recommended for use in the preprocedure setting, they have not been validated and their performance remains questionable. Vries et al. found that the International Society of Thrombosis and Haemostasis (ISTH) Bleeding Assessment Tool (BAT) questionnaire in the preoperative setting did not differentiate between patients with and without defined laboratory abnormalities.<sup>12</sup> Hence a consensus-based questionnaire, HEMSTOP (Hematoma, hEmorrhage, Menorrhagia, Surgery, Tooth extraction, Obstetrics, Parents), to assess preoperative bleeding risk was proposed.<sup>13</sup> This tool was developed to identify adults with bleeding symptoms for whom perioperative haemostatic

precautions should be considered. The HEMSTOP questionnaire contains five questions relevant to all patients and two gender-specific questions (Table 1). A HEMSTOP score of 2 or more had a specificity of 98.6% (95% confidence interval [CI], 92.3–100) and a sensitivity of 89.5% for patients requiring haemostatic precautions due to an elevated bleeding risk. With a HEMSTOP score of <2, the authors suggest that in a realistic prevalence scenario (bleeding disorder frequency of 1%), the negative predictive value would be >99%, essentially ruling out a patient-related bleeding risk requiring special precautions. The questionnaire is simple to apply and warrants further assessment and prospective validation. Although the study is too small to support a strong recommendation, it is felt that this score may have a role in the preassessment setting to indicate which patients need further haematological input. There are a number of additional caveats to consider. First, a positive score does not necessarily indicate a bleeding disorder with an estimated positive predictive value of 39%. Certain bleeding symptoms such as heavy menstrual bleeding and bruising are common in the normal population without haemostatic defects, whereas a lack of significant bleeding despite previous surgical or procedural interventions would suggest that a significant underlying bleeding disorder is unlikely. Second, there is a subjective element to the questions and so clinical judgement is required in interpretation, especially in patients already on antiplatelet agents or anticoagulants. Finally, although only 1.4% of healthy volunteers were found to have a score of 2 or more, this may not be reflective of the hospitalised population, and the capacity and resources to investigate patients identified through this tool remain unclear.<sup>14</sup>

MEDICATION HISTORY

Table 2 provides a list of antithrombotic and/or antiplatelet medications which should be highlighted in the assessment. The risk of bleeding associated with a procedure will determine the need to interrupt medication. The BSH has produced guidance for the perioperative management

of anticoagulation and antiplatelet therapy.<sup>15</sup> There is no evidence to support routine laboratory testing in patients on anticoagulants or antiplatelet agents prior to procedures other than checking the INR in patients on vitamin K antagonists.

All patients on antiplatelet agents and anticoagulants should be counselled about the risks of bleeding from invasive procedures versus thrombosis associated with interruption of treatment within the consent process. One meta-analysis identified a threefold increase in major cardiac adverse events in patients who discontinued aspirin therapy given as secondary prophylaxis and a smaller study showed a similar odds ratio for ischaemic stroke.<sup>16,17</sup> Although these observational studies are not specific to percutaneous procedures and high-quality evidence is lacking, it is reasonable to assume some thrombotic risk to patients from pausing anticoagulants and antiplatelet agents, albeit likely <1% in most situations. Using the perioperative anticoagulant use for surgery evaluation (PAUSE) protocol in patients with atrial fibrillation requiring interruption of apixaban, dabigatran or rivaroxaban for surgery or procedures with a high bleeding risk, the overall 30-day risk of bleeding was ≤1.69% and the risk of arterial thromboembolism was ≤0.5%. Only a small minority were interventional radiology procedures and many patients will not have restarted the direct oral anticoagulant (DOAC) until 2–3 days post procedure.<sup>18</sup> When measured, the residual anticoagulant level was <50 ng/mL in 98.8% of cases. Routine measurement of DOAC levels before procedures is therefore not indicated when using the PAUSE protocol and there is currently an absence of evidence to support a clinical utility from testing.

Many low-risk procedures can be performed without pausing anticoagulants and aspirin. Procedures documented as not being associated with an increased bleeding risk if low-dose aspirin is continued include transbronchial lung biopsy, percutaneous biopsies and renal biopsy.<sup>19–22</sup> For newer antiplatelet agents, much of the data are derived from experience in cardiac surgery rather than non-surgical procedures. In vitro experiments indicate significant differences in the duration of action and reversibility of P2Y12 inhibitors in comparison with aspirin. The effects of aspirin wear off within 4 days in comparison with 7–10 days following clopidogrel cessation.<sup>23</sup> A greater percentage of normal platelets is required to normalise platelet aggregation in the presence of platelets inhibited by clopidogrel in comparison with aspirin. Until further clinical data become available, a conservative approach with the newer antiplatelet agents is reasonable because in many procedures, adequacy of haemostasis cannot be directly visualised and direct interventions to stop active bleeding are not feasible.

After a procedure associated with immediate and complete haemostasis, for example, soft tissue biopsy without significant vascular injury, recommendations are that DOACs can be restarted at 6–8 h postprocedure. Pragmatically, this could be the patient's next routine dose beyond this time period.<sup>24</sup> The PAUSE protocol recommends restarting the day after the procedure for low-risk procedures and a delayed

TABLE 1 HEMSTOP questionnaire (each question scores 1 for yes).

1. Have you ever consulted a doctor or received treatment for prolonged or unusual bleeding (such as nosebleeds, minor wounds)?
2. Do you experience bruises/haematomas larger than 2 cm without trauma or severe bruising after minor trauma?
3. After a tooth extraction, have you ever experienced prolonged bleeding requiring medical/dental consultation?
4. Have you experienced excessive bleeding during or after surgery?
5. Is there anyone in your family who suffers from a coagulation disease (such as haemophilia and von Willebrand disease)?

*Additional questions for females*

6. Have you ever consulted a doctor or received treatment for heavy or prolonged menstrual periods (contraceptive pill, iron, etc.)?
7. Did you experience prolonged or excessive bleeding after delivery?

**TABLE 2** List of antithrombotic and antiplatelet medication with recommendations for management before elective and urgent procedures associated with bleeding risk.

Drug	Elective	Urgent	Notes
Aspirin	Continue unless high bleeding risk	Continue	Expected to correct within 4 days of stopping
Clopidogrel	Omit for 5–7 days	If cannot delay, consider stopping 24 h; tranexamic acid and platelet transfusion may be considered <sup>15</sup>	Patients on DAPT, prasugrel or ticagrelor should be discussed with a cardiologist
Prasugrel	Omit for 7 days		
Ticagrelor	Omit for 3–5 days		
Dipyridamole	Omit on the day of procedure		Reversible weak platelet inhibitor
Low-molecular-weight heparin (all risk procedures)	Prophylactic last dose >12 h preprocedure Higher than prophylactic last dose >24 h preprocedure		
Unfractionated heparin	Omit for 4–6 h	Consider protamine only if very urgent	
Parenteral direct thrombin Inhibitors (argatroban or bivalirudin)	≥4 h	There is no reversal agent	
Fondaparinux	Omit 1–2 days after prophylactic dose and ≥3 days after therapeutic dose	There is no reversal agent	Half-life is approximately 17 h. Prolonged further if abnormal renal function
Warfarin	Omit for 5 days	Consider reversal with intravenous (IV) vitamin K if ≥6 h before procedure and with 4F-PCC if <6–12 h	IV vitamin K will approximately halve the INR after 6 h Bridging with LMWH should be considered if high risk for thromboembolism, for example, recent VTE <3 months, APS, high INR target (>2.5) and AF with CHADS2 ≥5
Direct oral anticoagulants	Omit for 2 days preprocedure unless low bleeding risk	Discuss with a haematologist	Omit for >2 days for patients on dabigatran with impaired renal function Idarucizumab can be used to reverse dabigatran prior to urgent procedures Routine preprocedure testing of DOAC levels is not recommended

Abbreviations: 4F-PCC, four-factor prothrombin complex concentrate; AF, atrial fibrillation; APS, anti-phospholipid syndrome; DAPT, dual antiplatelet therapy; INR, international normalised ratio; IV, intravenous; VTE, venous thromboembolism.

restart after 2–3 days for high-risk procedures.<sup>18</sup> No high-quality data are available to guide the timing of restarting antiplatelet agents. However, the same timing could be applied as per DOACs unless there is a significant risk of delayed bleeding. Warfarin can be restarted on the evening of the procedure or the following day at the patient's usual dose.<sup>15</sup>

## COAGULATION TESTING

NICE NG45 has recommended against routine coagulation testing prior to elective surgical procedures.<sup>25</sup> In the previous BSH guidance, Chee et al. reviewed nine observational studies (three prospective) indicating a positive predictive value (0.03–0.22) and a likelihood ratio (0.94–5.1) for coagulation tests, concluding that the PT and APTT are poor predictors of bleeding.<sup>1</sup> A subsequent meta-analysis consisting predominantly of observational studies (in the absence

of a large randomised controlled trial [RCT]) has come to the same conclusion that unselected testing is not supported by evidence.<sup>26</sup> The clinical utility of the PT and APTT as a screening tool is therefore extremely limited.<sup>27</sup> This is not altogether unexpected as the PT and APTT are *in vitro* tests which can identify clinically irrelevant reductions in clotting factors such as *in vitro* inhibitors not associated with bleeding such as the lupus anticoagulant, and do not measure the complex haemostatic rebalancing seen in patients with acute illness and liver disease. In addition, many of the commonest bleeding disorders are not associated with an abnormal coagulation profile, including platelet function defects, mild VWD and even moderate factor deficiencies of clinical relevance.

Evidence has shown that extensive laboratory testing in patients with a bleeding history has significant limitations. Vries et al. found that patients with and without a bleeding history prior to procedures had a similar frequency of abnormal laboratory findings, reflecting the poor correlation of



many laboratory results with clinical phenotype.<sup>12</sup> To complicate matters further, patients with a clinically suspected mild bleeding disorder often remain uncharacterisable in terms of a defined laboratory abnormality, and the procedure-related bleeding risk is high even with prophylactic treatment.<sup>28-30</sup>

## GLOBAL HAEMOSTATIC AND PLATELET FUNCTION TESTING FOR PREDICTING BLEEDING PRIOR TO INVASIVE PROCEDURES

Devices such as platelet function analyser, multiple electrode platelet aggregometry (multiplate analyser), viscoelastic haemostatic assays (TEG/ROTEM) have all been used to assess bleeding risk prior to surgery or invasive procedures. This guideline does not cover the use of viscoelastic testing during surgery or the use of other established point-of-care (POC) tests such as the activated clotting time (CT) during cardiac bypass.

### Platelet function analyser (PFA-100/200)

There are no large prospective RCTs to date, but several small studies demonstrate that non-selective screening with the PFA has no predictive value for bleeding or transfusion requirement in patients undergoing invasive procedures, including those with renal failure.<sup>31-35</sup> Only Sucker et al. suggested a possible role for PFA in preoperative risk stratification based on 50 patients with aortic valve disease.<sup>36</sup>

### Multiple electrode platelet aggregometry

The multiple electrode platelet aggregometry (multiplate) detects the effects of aspirin (ASPItest), ADP receptor (P2Y12) inhibitors (clopidogrel, prasugrel and ticlopidine) (ADPtest) and GpIIb/IIIa antagonists (TRAPtest). The recovery of platelet reactivity following the discontinuation of P2Y12 receptor blockers is highly variable. Several studies have indicated that the assessment of platelet function using multiplate analysis can predict bleeding risk, thereby reducing blood product requirements.<sup>37-40</sup> This was confirmed by a systematic review (30 observational studies [3044 patients] and 9 RCTs [1057 patients]) and a meta-analysis of POC platelet function tests for predicting blood loss and transfusion requirements in cardiac surgical patients.<sup>41</sup> However, there are no comparable studies for other types of surgery.

### Viscoelastic testing: Thromboelastography (TEG) and thromboelastometry (ROTEM)

The value of TEG and ROTEM in the diagnosis of coagulopathy and the use of haemostatic support are discussed

in a separate BSH document.<sup>42</sup> Data on TEG/ROTEM in predicting bleeding or the use of blood products in patients without liver disease undergoing invasive procedures, and use within the critical care setting are limited. The level of evidence is low due to the heterogeneity in the design of the studies, use of different control groups, a lack of reference standards and variability in chosen end-points.<sup>43</sup> In a prospective pilot study of 119 patients in an intensive care unit (ICU), tracheostomy was performed without bleeding complications in cases with normal ROTEM results (EXTEM CT) despite increased PT-INR and without the administration of FFP.<sup>44</sup> In a retrospective study of 1879 ICU patients, there was a significant reduction in blood product use without any bleeding complications after the implementation of ROTEM prior to intervention.<sup>45</sup> In this study, if the prothrombin ratio was >1.5, the platelet count was  $>50 \times 10^9/L$  and the APTT ratio was <1.5, then ROTEM was performed. If the EXTEM CT was normal (40–80 s), then the procedure was performed without prophylactic FFP administration. As a consequence, FFP and platelet transfusion reduced by 35% and 3%, respectively in the first year and 52% and 20% in the second year after the introduction of ROTEM use.<sup>45</sup>

Evidence has shown that TEG and ROTEM parameters predict blood loss during liver transplantation.<sup>46-48</sup> De Pietri et al. randomised patients (60 patients with significant coagulopathy [INR >1.8/Platelets  $<50 \times 10^9/L$ ]) to standard of care (FFP/platelet transfusion) or TEG-guided transfusion prior to intervention.<sup>49</sup> Postprocedural bleeding occurred in only one patient post abdominal paracentesis. TEG-guided transfusion led to a significant reduction in blood product use without an increase in bleeding complications. This finding has been replicated with both TEG and ROTEM-guided transfusions prior to endoscopic procedures.<sup>50,51</sup> Emerging evidence suggests a potential role for TEG/ROTEM in reducing transfusion support in the periprocedural management of liver disease patients, with TEG maximum amplitude being a potential predictor of bleeding.<sup>52,53</sup> However, the lack of validated thresholds to guide haemostatic management necessitates further research to validate the efficacy of global haemostasis assays in this setting.

## PROPHYLACTIC USE OF PLASMA PRODUCTS PRIOR TO INVASIVE PROCEDURES

### Fresh frozen plasma

Numerous studies have demonstrated no significant benefit from using prophylactic FFP or cryoprecipitate prior to procedures in non-bleeding patients with abnormal clotting tests<sup>54-57</sup> with evidence that FFP transfusion in practice usually fails to correct abnormal PT ratio/INR values.<sup>58</sup> In a separate BSH guideline,<sup>59</sup> it is noted that the impact of commonly used doses of FFP to correct clotting results, or

**TABLE 3** Recommended platelet threshold for patients undergoing invasive procedures.

Procedure	Platelet threshold $\times 10^9/L$	Level of evidence
Venous central lines (both tunnelled and untunnelled), inserted by experienced staff using ultrasound guidance techniques	$\geq 20^a$	1B
Lumbar puncture	$\geq 40$	2C
Major surgery	$\geq 50$	1C
Minor surgery	$\geq 30$	1C
Insertion/removal of epidural catheter	$\geq 80^b$	2C
Neurosurgery or ophthalmic surgery involving the posterior segment of the eye	$\geq 100$	1C
Percutaneous liver biopsy	$\geq 50$	2B
Percutaneous renal biopsy	$\geq 50^c$	2D

Note: Adapted from the recommendation of the BSH guidelines on the use of platelet transfusions<sup>75</sup> and evidence review: the periprocedural use of blood products.<sup>76</sup>

<sup>a</sup>In patients requiring a tunnelled central venous catheter, a platelet count  $>30 \times 10^9/L$  may be a preferable target.<sup>77</sup>

<sup>b</sup>A platelet count of  $\geq 70$  has been recommended for epidural in otherwise stable patients with no bleeding concerns and  $\geq 50 \times 10^9/L$  for spinal anaesthetic where there are risk factors for general anaesthetic.<sup>78,79</sup>

<sup>c</sup>MacGinley et al.<sup>80</sup> A survey of Australasian renal physicians found that 52% preferred a threshold of  $100 \times 10^9/L$ .<sup>81</sup>

to reduce the bleeding risk, is very limited particularly when the PT ratio/INR is between 1.5 and 1.9.

## Fibrinogen replacement

Fibrinogen has a critical role in clot formation, providing a matrix and mesh network essential for clot strength.<sup>60</sup> Maintaining a haemostatic level of fibrinogen is an important therapeutic target in bleeding patients, particularly in the perioperative setting.<sup>61</sup> However, the level of fibrinogen required prior to an invasive procedure is yet to be determined. Transfusion guidelines have published conflicting optimal fibrinogen levels in patients with bleeding, or prior to intervention.<sup>59,62</sup> 'Normal' reported fibrinogen levels vary but are generally considered to range from 1.5 to 4.5 g/L.<sup>63,64</sup> POC coagulation testing using viscoelastic measurements of clot strength (maximal amplitude/maximum clot firmness) is also dependent on fibrinogen concentration.<sup>65</sup> The critical level of fibrinogen in maintaining haemostasis depends on multiple factors and clinical situations.<sup>66</sup> Consensus recommendations suggest fibrinogen levels of at least 1.5–2.0 g/L to achieve haemostasis in a patient with major bleeding or undergoing an invasive procedure.<sup>62,65,67</sup>

Furthermore, there can be both quantitative and acquired qualitative changes in fibrin formation. In the ISTH guidelines on the periprocedural management of abnormal coagulation parameters and thrombocytopenia in patients with cirrhosis, it is noted that in vitro tests suggest an enhanced thrombogenicity of the fibrin clot in patients with cirrhosis and that fibrinogen is rarely  $<1$  g/L in non-critically ill patients. They also suggest that fibrinogen should not be routinely measured in the non-critically ill prior to elective procedures.<sup>68</sup>

Fibrinogen replacement can be with cryoprecipitate or fibrinogen concentrates, and clinical practice varies according to their availability and licensing status.<sup>59,69</sup>

There is no evidence to support a specific fibrinogen level at which replacement should be given prior to an invasive procedure. However, this guideline recommends that in unwell hospitalised patients, replacement should be considered if the fibrinogen level in a critically unwell patient is  $<1.0$  g/L.<sup>70</sup>

## Platelet transfusion

The relationship between platelet count and bleeding risk is not linear and depends on platelet function and other patient-specific variables. Large studies suggest that the risk of spontaneous bleeding is difficult to predict until platelet count is reduced to approximately  $10 \times 10^9/L$ .<sup>71</sup> There are no high-quality data quantifying the bleeding risk according to platelet count in invasive procedures.

In one single-centre retrospective study of 18 204 patients undergoing interventional radiological procedures, prophylactic platelet transfusions did not reduce bleeding or improve clinical outcomes.<sup>72</sup> In patients with platelet counts  $<50 \times 10^9/L$ , prophylactic platelet transfusions did not reduce the use of red cell transfusion. In addition to platelet count, risk of bleeding is affected by factors such as the platelet function, presence of inflammation and cause of thrombocytopenia, for example, patients with immune thrombocytopenia were less likely to bleed.<sup>71</sup>

The most common indication for preprocedure platelet transfusion has been found to be central venous catheter insertion.<sup>73</sup> There is no strong evidence to indicate that preoperative testing of platelet levels is necessary prior to low bleeding risk procedures. Patients with haematological disorders that cause thrombocytopenia are one notable exception. Where known, platelet count should be  $>20 \times 10^9/L$ . However, platelet transfusion is almost always contraindicated in patients with thrombotic thrombocytopenic purpura. A systematic review of central venous catheter

placement in patients with platelet levels of  $<50 \times 10^9$  demonstrated no major bleeding complications.<sup>74</sup>

For high bleeding risk procedures, it is reasonable to check an up-to-date platelet count of any patient at risk of thrombocytopenia. Table 3 summarises suggested thresholds for platelet transfusion for different invasive procedures. Figures are based on low-quality evidence, expert opinion or practice review, with only a small number of RCTs of small sample size.<sup>75,82,83</sup> The value of platelet transfusion to achieve target levels remains uncertain, especially in patients with liver disease and portal hypertension.

## SPECIAL POPULATIONS

### Patients with liver disease

Both acute and chronic liver disease is associated with distinct changes in haemostatic and haemodynamic pathways. The liver is the major site for the synthesis of many pro-coagulant and anticoagulant factors. Therefore, the PT, APTT and fibrinogen are markers of synthetic function, but nevertheless conventional in vitro tests of coagulation are of limited value in assessing overall haemostatic competency in liver disease.

Liver disease promotes complex haemostatic abnormalities with increases in factor VIII and von Willebrand factor and deficiency of other pro-coagulant and anticoagulant factors, endothelial dysfunction, reduced platelet count/function, low-level activation of the coagulation system and hypo- and hyperfibrinolysis. These fluctuations have led to the concept of rebalanced coagulopathy in acute and chronic liver disease—a clinical state that is supported by clinical and laboratory data, often to a marginally pro-thrombotic state.<sup>84-89</sup> However, acute-on-chronic decompensated liver failure (ACLF) and other factors such as acute kidney injury or infection may impact on this rebalancing and increase the risk of bleeding.<sup>52,89,90,91,92</sup> ACLF that is associated with an acute inflammatory response may also result in hyperfibrinolysis and coagulopathy with platelet dysfunction that increases bleeding risk.<sup>93</sup> In one study, a platelet count  $<30 \times 10^9/L$ , fibrinogen level  $<0.6\text{ g/L}$  and APTT values  $>100\text{ s}$  were the strongest independent predictors of the new onset of major bleeding although portal hypertension was a key factor. All but the most essential invasive procedures should be avoided under these circumstances.<sup>91,94</sup>

The use of INR to guide bleeding risk following invasive procedures in liver patients is not supported by clinical evidence. No clinical trials have established precise thresholds for PT and APTT at which invasive procedures can be considered safe. A number of studies have investigated the safety of liver biopsy in patients with coagulopathy, with data indicating that bleeding does not correlate with indices of peripheral coagulation.<sup>95-100</sup> Conversely, there is also evidence suggesting a weak association between bleeding and INR, acknowledging a substantial overlap of INR and platelet count between bleeders and non-bleeders.<sup>101-103</sup>

Portal hypertension, the presence of venous collaterals and other anatomical changes related to liver cirrhosis may modify bleeding risk following liver biopsy, for which the INR is just a surrogate marker.<sup>94</sup> An observational study of 302 patients undergoing liver biopsy and comprehensive haemostatic profiling (thrombin generation, ROTEM, clot lysis assays and PFA-100) found no association between haemostatic profiles and procedural bleeding.<sup>104</sup> Indeed, the only identified predictor of bleeding was pain 2 h post procedure.

A broad overview of the literature demonstrates low rates of bleeding complications in hepatology patients undergoing invasive procedures. Townsend et al. reported no major bleeding complications in 240 end-stage liver patients (INR 0.93–2.35) undergoing cardiac catheterisation.<sup>105</sup> Puchalski et al. reported that thoracentesis can be performed safely in patients with prolonged INR ( $>1.5$ ), secondary to either warfarin or liver disease, without correction of coagulopathy.<sup>57</sup> Somani et al. found that only 1/150 patients experienced significant bleeding after a range of invasive procedures, including liver biopsy, pleural tap, intercostal drain insertion and central venous catheterisation, although severe coagulation abnormalities (INR  $>1.8$ ) were present in only 25% of patients.<sup>106</sup> Shah et al. undertook a prospective study of 380 patients with cirrhosis undergoing invasive procedures.<sup>107</sup> Patients were divided into two groups according to the presence or absence of coagulopathy (defined as INR  $>1.5$  and/or platelet count  $<50 \times 10^9/L$ ). No bleeding events were seen in either group following low-risk procedures such as paracentesis. However, there was an increased risk of bleeding in the coagulopathic group following high-risk procedures or liver biopsy, although this was not statistically significant.<sup>107</sup> Napolitano et al. reported a prospective study of 852 invasive procedures in 363 cirrhotic patients. Postprocedure bleeding was rare (1.2%) and not predicted by low platelets or prolonged INR.<sup>108</sup> The analysis of 1076 ultrasound-guided thoracentesis cases found no haemorrhagic complications even in the 139 cases where INR was  $>2.0$ ; another study of thoracenteses showed no evidence of haemothorax in any of the 312 patients undergoing the procedure (including 44 patients with INR  $>1.5$ ).<sup>56,57</sup> A larger study of 9320 thoracentesis procedures (2306 with an INR  $\geq 1.5$ ) showed only 17 bleeding complications with no association between INR and bleeding.<sup>109</sup> A study of 3117 ultrasound-guided paracentesis cases found major haemorrhage to be extremely rare, with only six cases identified, despite INR being  $>2.0$  in 437 cases.<sup>110</sup> A large prospective multicentre observational study of procedural bleeding in 1187 hospitalised patients with decompensated cirrhosis or ACLF undergoing 3006 procedures reported an overall low incidence of major bleeding (0.9% of procedures).<sup>111</sup> No relationship was identified between INR, platelet count and procedural bleeding. Independent predictors of bleeding were high bleeding risk procedures (OR 4.6, 95% CI: 2.4–8.4), liver disease severity (evaluated with model for end-stage liver disease OR 2.37, 95% CI: 1.5–3.9) and body mass index (OR 1.4, 95% CI: 1.1–1.8).



Table 4 shows a list of low bleeding risk procedures and guidelines have recommended against routinely correcting thrombocytopenia and coagulopathy in this setting.

Conventional haemostasis assays have been used prior to invasive tests both to risk stratify patients and to guide therapeutic correction of coagulation abnormalities. However, there is no evidence that prophylactic transfusion of blood products such as FFP or platelets reduces haemostatic complications following invasive procedures.<sup>113</sup> Transfusion of FFP appears to be at best ineffective and may cause harm.<sup>114-117</sup> Thrombin generation in cirrhotic patients does not appreciably change after supplementation with pooled normal plasma despite reductions in PT and may enhance an existing prothrombotic state.<sup>118-120</sup> An increasing number of international guidelines now advise against the prophylactic use of FFP before invasive procedures.<sup>68,112,121,122,123</sup>

There is no evidence to support the use of vitamin K replacement in patients with cirrhosis. In a retrospective study of 85 patients, the majority with Child–Pugh class C cirrhosis, the absolute change in INR was  $-0.07 \pm 0.35$  following vitamin K administration. There was no difference in absolute INR change between single versus multiple dose administration or between PO versus IV administration.<sup>124</sup>

In a study of 497 patients receiving 10 mg IV vitamin K for 3 days, two-thirds of patients with cirrhosis had no improvement in the INR and those that did show a partial response were more likely to have alcoholic cirrhosis.<sup>125</sup> It continues to be acceptable to consider high-dose IV vitamin K replacement in patients with an increased INR secondary to vitamin K deficiency, for example, cholestatic liver disease, malnutrition or prolonged antibiotic use.<sup>93,94,112,126</sup> However, procedures should not be delayed awaiting INR confirmation if an adequate dose has been given (e.g. 10 mg IV) and a suitable time interval has elapsed (>6 h).

There are no prospective studies evaluating the periprocedural role of cryoprecipitate/fibrinogen concentrates in cirrhotic patients and no evidence to support the use of prothrombin complex concentrate (PCC) or recombinant factor VIIa or tranexamic acid periprocedure. Concern exists about the potential harm with PCC in ACLF.<sup>68,127</sup>

Anti-fibrinolytic therapy has been recommended as an option in patients with postprocedure bleeding when there is evidence of hyperfibrinolysis, but guidelines have not

recommended routine tranexamic acid prophylaxis prior to procedures. The HALT-IT study indicates that exposure to continuous tranexamic acid for 24 h may increase the risk of venous thrombosis in patients with liver disease.<sup>112,121</sup>

Evidence for a platelet threshold above which invasive procedures can be safely performed is limited. In vitro studies using plasma from cirrhotic patients show that a platelet count  $>56 \times 10^9/L$  allows thrombin generation above the 10th percentile of the healthy population.<sup>118</sup> In a study of liver biopsies in patients with hepatitis C infection, bleeding rate was the highest in patients with a platelet count  $<60 \times 10^9/L$ . However, the majority of bleeds occurred in patients with platelet count  $>100 \times 10^9/L$ .<sup>128</sup> As with the INR, the platelet count may also be a surrogate marker for risk factors such as fibrosis and portal hypertension. In one large retrospective study of patients undergoing percutaneous liver biopsy, the implementation of less stringent guidelines for preprocedure blood product (FFP/platelet) use (INR  $\geq 2$  and platelets  $<25 \times 10^9/L$ ) was associated with fewer haemorrhagic complications than historical cut-offs (INR  $\geq 1.5$  and platelets  $\leq 50 \times 10^9/L$ ).<sup>129</sup>

In cirrhotic patients, transfusion of a single pool of platelets results in only a small increase in platelet count without normalising either thrombin generation or TEG tests and may be associated with harmful transfusion reactions.<sup>130</sup>

TPO-RAs are now available for use prior to elective procedures in thrombocytopenic patients with liver disease, as an alternative to platelet transfusion. TPO-RAs may be preferable to platelet transfusion.<sup>112</sup> The treatment period required prior to intervention is 9–14 days. Although not seen in all studies, TPO-RAs have been associated with an increased risk of thrombosis, including portal vein thrombosis so should be used with caution in patients considered to be prothrombotic, especially as these patients were excluded from investigative trials.<sup>94,131</sup> Although TPO-RAs appear more effective in increasing platelet counts compared to platelet transfusion, there remains uncertainty regarding impact on bleeding risk.<sup>132,133</sup>

To optimise clot formation in advanced liver disease, the American Gastroenterology Association guidelines recommend transfusion thresholds during active bleeding or prior to high-risk procedures of haematocrit  $\geq 25\%$ , platelet count  $>50 \times 10^9/L$  and fibrinogen  $>1.2 \text{ g/L}$ .<sup>112</sup>

## The critical care patient

In critical care patients, acquired coagulation (PT, APTT and INR) abnormalities are common. In a UK prospective study (ISOC-1), 30% of patients had an INR  $>1.5$  at some point during their admission.<sup>134</sup> Most derangements are short term and mild (INR  $<2.5$ ) but are independently associated with a significantly increased risk of death even adjusting for illness severity.<sup>135-137</sup> Sepsis is associated with both a quantitative and qualitative impact on platelets.<sup>138,139</sup> Thrombocytopenia is also common in this patient group with up to 60% being thrombocytopenic at critical care

**TABLE 4** Low bleeding risk procedures performed in patients with chronic liver disease.

Diagnostic endoscopic procedures and variceal ligation
Transoesophageal echocardiogram
Paracentesis
Thoracentesis
Peripheral venous line insertion/central venous catheter exchange or removal
Dental procedures including extractions
Skin biopsy

Note: Adapted from Refs [68,112].

admission and 13%–44% developing thrombocytopenia while in the ICU.<sup>140</sup> A multicentre observational study in the United Kingdom reported 13% of patients had a platelet count  $<50 \times 10^9/L$ .<sup>137</sup>

Taking a clinical history on the ICU may be impractical, and the conventional tests of coagulation neither reflect *in vivo* haemostasis nor predict procedure-related bleeding.<sup>44,141,142,143,144,145,146</sup> Invasive procedures including the insertion of vascular access catheters, percutaneous tracheostomy and thoracentesis are common in critical care, and observational data suggest these can be carried out with a low risk of bleeding.<sup>137,139,142,146,147,148</sup>

Plasma products are frequently administered to patients in ICU without any evidence to support this practice. In a 2011 UK multicentre observational study of 1923 ICU admissions, 31% of the 404 FFP treatment episodes were to patients without PT prolongation, and 41% were to patients without recorded bleeding and only mildly deranged INR ( $<2.5$ ). Procedural prophylaxis was the documented transfusion reason in 15%.<sup>136,137</sup> Evidence that FFP prevents periprocedural bleeding complications in the non-bleeding critical care patients is lacking.<sup>74,134,144,149</sup>

The TOPIC trial assigned 81 ICU patients with an INR of 1.5–3 to receive either no FFP or 12 mL/kg FFP prior to central venous catheter insertion, tracheostomy, chest drain insertion or abscess drainage.<sup>55</sup> There was no significant difference between the two groups in terms of postprocedural bleeding, although the study was limited by its small size. The dose of FFP was sufficient to correct the INR to  $<1.5$  in only 54% of patients. Coagulation factor assays at baseline suggested a similar rebalancing to that seen in liver disease, with reduction in natural anticoagulants as well as pro-coagulant factors, along with normal viscoelastic testing and normal thrombin generation in the great majority.<sup>150</sup> FFP can be associated with transfusion-associated circulatory overload which is the leading cause of transfusion-related death, multiorgan failure and increased susceptibility to infection.<sup>59,151,152</sup>

Platelet transfusions are also commonly administered without evidence to support this practice. The aforementioned, multicentre UK study of 1923 critically ill patients found 9% received platelet transfusion during their admission. Of the 534 treatment episodes, 40% of patients had a platelet count  $>50 \times 10^9/L$  at the time of transfusion and 55% of patients were not bleeding at the time of administration.<sup>149</sup> The median increment in platelet count was  $15 \times 10^9/L$  (interquartile range  $2\text{--}35.5 \times 10^9/L$ ). Similar findings were reported in a multicentre observational audit in Australasia, with 33% of platelet transfusions given to simply prevent procedural bleeding.<sup>153</sup> There is a lack of evidence to support prophylactic platelet transfusion in the periprocedural setting.<sup>75,154</sup>

A recent non-inferiority RCT of platelet transfusion versus no intervention prior to central venous catheter insertion in haematology patients with a platelet count of  $10\text{--}50 \times 10^9/L$  (including 161 ICU patients) reported a reduction in major bleeding in the platelet transfusion cohort (defined as WHO

grade  $\geq 2$ ).<sup>77</sup> Sensitivity analyses suggest platelet transfusion reduced bleeding specifically in patients either undergoing subclavian line insertion or in those with platelet count  $<30 \times 10^9/L$ . Major bleeding rates were higher in patients undergoing tunnelled line insertion. A small RCT in critically ill patients with severe thrombocytopenia undergoing tracheostomy ( $n=57$ ) reported no difference in blood loss between those receiving platelet transfusion and those without.<sup>155</sup> Platelet transfusion in non-critical care settings has been associated with adverse patient outcomes, particularly increased mortality.<sup>156</sup>

## OPERATOR AND PROCEDURAL RISK FACTORS FOR BLEEDING

The risk of periprocedural bleeding may also be increased or mitigated by operator and technical factors as well as patient anatomy and physiology independent of haemostatic disorders and medication.

Measures to reduce the risk of procedural bleeding should always be considered (Table 5). A meta-analysis evaluating femoral artery access with and without the use of ultrasound guidance showed a significant reduction in vascular complications when ultrasound guidance was used, with fewer needle passes required.<sup>169</sup> Reduced number of passes and fewer complications have also been observed in central venous catheter insertion when using ultrasound compared with the traditional landmark technique.<sup>74</sup> Although some operators favour micropuncture needles in arterial or venous access, there are no clear data to suggest a benefit in terms of bleeding risk reduction.<sup>170,171</sup> This is also illustrated by Strobel et al. examining percutaneous intra-abdominal interventions and Atwell et al. examining percutaneous biopsy. Both trials showed no significant increase in major bleeding when larger needles were used.<sup>20,172</sup> It has been suggested that procedures requiring an arterial access sheath size of more than 7 French should be considered high risk. Furthermore, there are mixed data regarding whether vascular closure devices are protective against access site haemorrhage.<sup>3,173</sup>

Operator experience and familiarity with particular techniques are also important. Data have shown a higher incidence of femoral artery access bleeding complications when this approach is used by experienced cardiologists, who primarily use radial artery access for intervention. Lower rates of major bleeding are also documented at high-volume centres.<sup>174,175</sup>

Sznadger et al. considered 50 procedures to be the threshold for competency of central venous catheter insertion, with significantly higher complication rates reported among inexperienced operators.<sup>157,158</sup> Despite this, a meta-analysis of bleeding complications post liver biopsy highlighted conflicting data on its relationship with operator experience. Conversely, another study showed a significantly higher bleeding complication rate from operators adjudged to be experienced compared to their less experienced

**TABLE 5** Operator, procedural and patient factors associated with the risk of procedural bleeding.

Operator factors	Evidence	Recommendation
Operator experience	More experienced operators have fewer complications for vascular/body cavity access, drainages/catheterisation <sup>101,157,158,159</sup>	High-risk procedures should be undertaken or assisted by a suitably experienced operator
Procedural factors	Evidence	Recommendations
Use of ultrasound	Non-RCT evidence indicates the use of image guidance is associated with a lower bleeding risk for vascular access, organ biopsy and body cavity drainage <sup>157-162</sup> Reduction of puncture frequency decreases overall complication rate for femoral venous access but not for bleeding risk <sup>158,161</sup> Decreased risk for paracentesis and thoracentesis <sup>163</sup>	Ultrasound image guidance should be used when available
Choice of equipment	Evidence is lacking; however, small-bore vascular access and chest drain catheters may reduce incidence of bleeding <sup>158</sup>	Use the smallest appropriate size of catheter/drain for any procedure
Choice of technique	Ultrasound-guided venous access reduces bleeding <sup>158,164</sup> Midline approach to paracentesis reduces risk <i>Transjugular approach can be considered for liver biopsy in patients with increased risk of bleeding</i> <sup>94</sup>	Consider anatomical factors
Unfavourable anatomy, prior surgery or radiotherapy	Lumbar puncture; ankylosing spondylitis, spinal stenosis <sup>165</sup>	Recommend use of ultrasound, optimal patient positioning, detailed anatomical knowledge and experienced operator
Patient factors	Evidence	Recommendations
Age	Risk factor for cardiac surgery and renal biopsy <sup>161,166</sup>	High-risk procedures should be undertaken or assisted by an experienced operator, if patient of an advanced age
Hypertension Systolic >160 mmHg Diastolic >100 mmHg MAP >120 mmHg	Increased risk of postrenal biopsy bleeding <sup>111,162</sup> Evidence suggests surgical procedures should not be delayed but hypertension treated >180/110 with antihypertensive medications <sup>167</sup>	Seek history of hypertension Experienced operator Enhanced postoperative monitoring Consider oral antihypertensive agent
High serum creatinine	Marker of a higher risk procedure—with increased risk of bleeding postrenal biopsy >177 µmol/L, <sup>168</sup> and thoracentesis >520 µmol/L <sup>96</sup> Correlation between renal disease and paracentesis haemorrhagic risk <sup>158</sup>	Experienced operator Enhanced postoperative monitoring
Obesity	Increased risk of failure of landmark-based intervention; lumbar puncture <sup>158,165</sup>	Image guidance; fluoroscopy/ultrasound
Red cell volume/haematocrit	Preoperative anaemia or small body size is a risk factor for blood transfusion in cardiac surgery <sup>166</sup>	Experienced operator Enhanced postoperative monitoring
Infection	Increases the risk of bleeding in patients with acute-on-chronic liver failure <sup>90</sup>	Treat infection

Abbreviations: MAP, mean arterial pressure; RCT, randomised controlled trial.

counterparts.<sup>160</sup> However, this finding is thought to be explained by a more complex/higher risk cohort of cases undertaken.<sup>176</sup>

## AUTHOR CONTRIBUTIONS

Will Lester chaired the writing group. All authors contributed to writing, editing and reviewing the manuscript, including the final submission.

## ACKNOWLEDGEMENTS

BSH Haemostasis and Thrombosis Task Force members over the time of writing this guideline were Keith Gomez, Khalid Saja, Renu Riat, Karen Breen, Sean Platten, Peter Baker, Lara Roberts, Jayashree Motwani and Ian Jennings. The authors would like to thank Barbara Bain, the BSH sounding board, and the BSH Guidelines Committee for their support in preparing this guideline.

## CONFLICT OF INTEREST STATEMENT

The BSH paid the expenses incurred during the writing of this guidance. All authors have made a full declaration of interests to the BSH and Task Force Chairs, which may be viewed on request. The authors have no relevant conflicts of interest to declare relating to this guideline.

## REVIEW PROCESS

Members of the writing group will inform the writing group chair if any new evidence becomes available that would alter the strength of the recommendations made in this document or render it obsolete. The document will be reviewed regularly by the relevant Task Force. The document will be archived and removed from the BSH current guidelines website if it becomes obsolete. If new recommendations are made, an addendum will be published on the BSH guidelines website ([www.b-s-h.org.uk/guidelines](http://www.b-s-h.org.uk/guidelines)).

## DISCLAIMER

While the advice and information in this guidance is believed to be true and accurate at the time of going to press, neither the authors, the BSH nor the publishers accept any legal responsibility for the content of this guidance.

## PERMISSION TO REPRODUCE MATERIAL FROM OTHER SOURCES

Adapted tables are referenced.

## ORCID

Will Lester  <https://orcid.org/0000-0001-8790-7112>

Raza Alikhan  <https://orcid.org/0000-0001-8762-1149>

Lara Roberts  <https://orcid.org/0000-0003-3871-8491>

## TWITTER

Will Lester  will\_a\_lester

the BSH Committee  BritSocHaem

## REFERENCES

- Chee YL, Crawford JC, Watson HG, Greaves M. Guidelines on the assessment of bleeding risk prior to surgery or invasive procedures. British Committee for Standards in Haematology. Br J Haematol. 2008;140(5):496–504.
- British Society of Interventional Radiology, British Society of Haematology. BSH Joint Guidance from the British Societies of Interventional Radiology and Haematology on Managing Bleeding Risk during Procedures in Interventional Radiology [Internet] [cited 2023 Aug 11]. Available from: <https://b-s-h.org.uk/guidelines/guidelines/joint-guidance-from-the-british-societies-of-interventional-radiology-and-haematology-on-managing-bleeding-risk-during-procedures-in-interventional-radiology>
- Patel IJ, Rahim S, Davidson JC, Hanks SE, Tam AL, Walker TG, et al. Society of Interventional radiology consensus guidelines for the periprocedural management of thrombotic and bleeding risk in patients undergoing percutaneous image-guided interventions-part II: recommendations: endorsed by the Canadian Association for Interventional Radiology and the Cardiovascular and Interventional Radiological Society of Europe. J Vasc Interv Radiol. 2019;30(8):1168–1184.e1.
- Atwell TD, Wennberg PW, McMenomy BP, Murthy NS, Anderson JR, Kriegshauser JS, et al. Peri-procedural use of anticoagulants in radiology: an evidence-based review. Abdom Radiol. 2017;42(5):1556–65.
- Baron TH, Kamath PS, McBane RD. Management of antithrombotic therapy in patients undergoing invasive procedures. N Engl J Med. 2013;368(22):2113–24.
- Kozek-Langenecker SA, Ahmed AB, Afshari A, Albaladejo P, Aldecoa C, Barauskas G, et al. Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology: first update 2016. Eur J Anaesthesiol. 2017;34(6):332–95.
- Baron DM, Metnitz PGH, Fellinger T, Metnitz B, Rhodes A, Kozek-Langenecker SA. Evaluation of clinical practice in perioperative patient blood management. Br J Anaesth. 2016;117(5):610–6.
- Tosetto A, Rodeghiero F, Castaman G, Goodeve A, Federici AB, Batlle J, et al. A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMMD-1 VWD). J Thromb Haemost. 2006;4(4):766–73.
- Bowman M, Mundell G, Grabel J, Hopman WM, Rapson D, Lillicrap D, et al. Generation and validation of the Condensed MCMMD-1VWD Bleeding Questionnaire for von Willebrand disease. J Thromb Haemost. 2008;6(12):2062–6.
- Bowman M, Riddel J, Rand ML, Tosetto A, Silva M, James PD. Evaluation of the diagnostic utility for von Willebrand disease of a pediatric bleeding questionnaire. J Thromb Haemost. 2009;7(8):1418–21.
- Rodeghiero F, Tosetto A, Abshire T, Arnold DM, Coller B, James P, et al. ISTH/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders. J Thromb Haemost. 2010;8(9):2063–5.
- Vries MJ, van der Meijden PE, Kuiper GJ, Nelemans PJ, Wetzels RJ, van Oerle RG, et al. Preoperative screening for bleeding disorders: a comprehensive laboratory assessment of clinical practice. Res Pract Thromb Haemost. 2018;2(4):767–77.
- Bonhomme F, Boehlen F, Clergue F, de Moerloose P. Preoperative hemostatic assessment: a new and simple bleeding questionnaire. Can J Anaesth. 2016;63(9):1007–15.
- Ranucci M. Detection of inherited and acquired hemostatic disorders in surgical patients. Can J Anaesth. 2016;63(9):1003–6.
- Keeling D, Tait RC, Watson H. British Committee of Standards for Haematology. Peri-operative management of anticoagulation and antiplatelet therapy. Br J Haematol. 2016;175(4):602–13.
- Biondi-Zoccai GGL, Lotrionte M, Agostoni P, Abbate A, Fusaro M, Burzotta F, et al. A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease. Eur Heart J. 2006;27(22):2667–74.
- Maulaz AB, Bezerra DC, Michel P, Bogousslavsky J. Effect of discontinuing aspirin therapy on the risk of brain ischemic stroke. Arch Neurol. 2005;62(8):1217–20.
- Douketis JD, Spyropoulos AC, Duncan J, Carrier M, Le Gal G, Tafur AJ, et al. Perioperative management of patients with atrial fibrillation receiving a direct oral anticoagulant. JAMA Intern Med. 2019;179(11):1469–78.
- Herth FJF, Ernst A, Becker HD. Endobronchial ultrasound-guided transbronchial lung biopsy in solitary pulmonary nodules and peripheral lesions. Eur Respir J. 2002;20(4):972–4.
- Atwell TD, Smith RL, Hesley GK, Callstrom MR, Schleck CD, Harmsen WS, et al. Incidence of bleeding after 15,181 percutaneous biopsies and the role of aspirin. AJR Am J Roentgenol. 2010;194(3):784–9.
- Lees JS, McQuarrie EP, Mordi N, Geddes CC, Fox JG, Mackinnon B. Risk factors for bleeding complications after nephrologist-performed native renal biopsy. Clin Kidney J. 2017;10(4):573–7.
- Bakdash K, Schramm KM, Annam A, Brown M, Kondo K, Lindquist JD. Complications of percutaneous renal biopsy. Semin Interv Radiol. 2019;36(2):97–103.
- Li C, Hirsh J, Xie C, Johnston M, Eikelboom JW. Reversal of the anti-platelet effects of aspirin and clopidogrel. J Thromb Haemost. 2012;10(4):521–8.



24. Heidbuchel H, Verhamme P, Alings M, Antz M, Diener HC, Hacke W, et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. *Europace*. 2015;17(10):1467–507.
25. NICE. Routine preoperative tests for elective surgery (NG45) [Internet]. NICE. 2020 [cited 2023 Aug 11]. Available from: <https://www.nice.org.uk/guidance/ng45>
26. Lontos L, Fralick M, Longmore A, Hicks LK, Sholzberg M. Bleeding rRisk Using INR/aPTT Pre-Surgery: systemtic Review (BRUISR). *Blood*. 2017;8(130):4654.
27. Capoor MN, Stonemetz JL, Baird JC, Ahmed FS, Awan A, Birkenmaier C, et al. Prothrombin time and activated partial thromboplastin time testing: a comparative effectiveness study in a million-patient sample. *PLoS One*. 2015;10(8):e0133317.
28. Gebhart J, Hofer S, Panzer S, Quehenberger P, Sunder-Plassmann R, Hoermann G, et al. High proportion of patients with bleeding of unknown cause in persons with a mild-to-moderate bleeding tendency: results from the Vienna Bleeding Biobank (VIBB). *Haemophilia*. 2018;24(3):405–13.
29. Mezzano D, Quiroga T. Diagnostic challenges of inherited mild bleeding disorders: a bait for poorly explored clinical and basic research. *J Thromb Haemost*. 2019;17(2):257–70.
30. van der Veen L, Segers M, van Raay JJ, Gerritsma-Bleeker CL, Brouwer RW, Veeger NJ, et al. Bleeding complications of thromboprophylaxis with dabigatran, nadroparin or rivaroxaban for 6 weeks after total knee arthroplasty surgery: a randomised pilot study. *BMJ Open*. 2021;11(1):e040336.
31. Ertug Z, Celik U, Hadimioglu N, Dinckan A, Ozdem S. The assessment of PFA-100 test for the estimation of blood loss in renal transplantation operation. *Ann Transplant*. 2010;15(1):46–52.
32. Karger R, Reuter K, Rohlf J, Nimsky C, Sure U, Kretschmer V. The platelet function analyzer (PFA-100) as a screening tool in neurosurgery. *ISRN Hematol*. 2012;2012:839242.
33. Lee AJ, Kim SG. Utility of preoperative in vitro platelet function tests for predicting bleeding risk in patients undergoing functional endoscopic sinus surgery. *J Blood Med*. 2016;7:235–8.
34. Prohaska W, Zittermann A, Inoue K, Tenderich G, Lüth JU, Köster-Eiserfunke W, et al. Preoperative haemostasis testing does not predict requirement of blood products in cardiac surgery. *Eur J Med Res*. 2008;13(11):525–30.
35. Jeon YL, Lee WI, Kang SY, Kim MH. Limitations of preoperative PFA-200 as a predictor of postoperative blood loss in total knee arthroplasty: according to use of tranexamic acid. *Clin Lab*. 2017;63(7):1121–8.
36. Sucker C, Litmathe J, Feindt P, Zotz R. Platelet function analyzer (PFA-100) as a useful tool for the prediction of transfusion requirements during aortic valve replacement. *Thorac Cardiovasc Surg*. 2011;59(4):233–6.
37. Ellis J, Valencia O, Crerar-Gilbert A, Phillips S, Meeran H, Sharma V. Point-of-care platelet function testing to predict blood loss after coronary artery bypass grafting surgery: a prospective observational pilot study. *Perfusion*. 2016;31(8):676–82.
38. Mishra PK, Thekkudan J, Sahajanandan R, Gravenor M, Lakshmanan S, Fayaz KM, et al. The role of point-of-care assessment of platelet function in predicting postoperative bleeding and transfusion requirements after coronary artery bypass grafting. *Ann Card Anaesth*. 2015;18(1):45–51.
39. Schimmer C, Hamouda K, Sommer SP, Özkur M, Hain J, Leyh R. The predictive value of multiple electrode platelet aggregometry (multiplate) in adult cardiac surgery. *Thorac Cardiovasc Surg*. 2013;61(8):733–43.
40. Vlot EA, Willemsen LM, Van Dongen EPA, Janssen PW, Hackeng CM, Kloppenburg GTL, et al. Perioperative point of care platelet function testing and postoperative blood loss in high-risk cardiac surgery patients. *Platelets*. 2019;30(8):982–8.
41. Corredor C, Wasowicz M, Karkouti K, Sharma V. The role of point-of-care platelet function testing in predicting postoperative bleeding following cardiac surgery: a systematic review and meta-analysis. *Anaesthesia*. 2015;70(6):715–31.
42. Curry NS, Davenport R, Pavord S, Mallett SV, Kitchen D, Klein AA, et al. The use of viscoelastic haemostatic assays in the management of major bleeding: a British Society for Haematology Guideline. *Br J Haematol*. 2018;182(6):789–806.
43. Görlinger K, Saner FH. Prophylactic plasma and platelet transfusion in the critically ill patient: just useless and expensive or even harmful? *BMC Anesthesiol*. 2015;15:86.
44. Durila M, Lukáš P, Astraverkhava M, Beroušek J, Záborský M, Vymazal T. Tracheostomy in intensive care unit patients can be performed without bleeding complications in case of normal thromboelastometry results (EXTEM CT) despite increased PT-INR: a prospective pilot study. *BMC Anesthesiol*. 2015;15:89.
45. Vymazal T, Astraverkhava M, Durila M. Rotational thromboelastometry helps to reduce blood product consumption in critically ill patients during small surgical procedures at the intensive care unit – a retrospective clinical analysis and literature search. *Transfus Med Hemother*. 2018;45(6):385–7.
46. Lawson PJ, Moore HB, Moore EE, Stettler GR, Pshak T, Kam I, et al. Preoperative TEG maximum amplitude predicts massive transfusion in liver transplantation. *J Surg Res*. 2017;220:171–5.
47. Sabate A, Blasi A, Costa M, Reyes R, Beltran J, Torres F. Assessment of rotational thromboelastometry for the prediction of red blood cell requirements in orthotopic liver transplantation. *Minerva Anesthesiol*. 2018;84(4):447–54.
48. Tafur LA, Taura P, Blasi A, Beltran J, Martinez-Palli G, Balust J, et al. Rotation thromboelastometry velocity curve predicts blood loss during liver transplantation. *Br J Anaesth*. 2016;117(6):741–8.
49. De Pietri L, Bianchini M, Montalti R, De Maria N, Di Maira T, Begliomini B, et al. Thrombelastography-guided blood product use before invasive procedures in cirrhosis with severe coagulopathy: a randomized, controlled trial. *Hepatology*. 2016;63(2):566–73.
50. Marocchi M, Bianchini M, De Pietri L, Bolondi G, Merighi A, Olivetti G. Thromboelastography-guided transfusions reduces the use of blood products in cirrhotic patients undergoing invasive endoscopic procedures. *Dig Liver Dis*. 2017;49:e113.
51. Smart L, Wellner M, Gray NA, Michaels A, Kirkpatrick RB, Conteh L. A prospective, randomized clinical trial comparing blood product use, bleeding events, and cost during and after endoscopic procedures in patients with cirrhosis and coagulopathy: rotational thromboelastometry (ROTEM) versus conventional therapy. *Hepatology*. 2017;66:243A–44A.
52. Zanetto A, Rinder HM, Senzolo M, Simioni P, Garcia-Tsao G. Reduced clot stability by thromboelastography as a potential indicator of procedure-related bleeding in decompensated cirrhosis. *Hepatol Commun*. 2021;5(2):272–82.
53. Shenoy A, Louissaint J, Shannon C, Tapper EB, Lok AS. Viscoelastic testing prior to non-surgical procedures reduces blood product use without increasing bleeding risk in cirrhosis. *Dig Dis Sci*. 2022;67(11):5290–9.
54. Hoang NS, Kothary N, Saharan S, Rosenberg J, Tran AA, Brown SB, et al. Administering blood products before selected interventional radiology procedures: developing, applying, and monitoring a standardized protocol. *J Am Coll Radiol*. 2017;14(11):1438–43.
55. Müller MCA, Straat M, Meijers JCM, Klinkspoor JH, de Jonge E, Arbous MS, et al. Fresh frozen plasma transfusion fails to influence the hemostatic balance in critically ill patients with a coagulopathy. *J Thromb Haemost*. 2015;13(6):989–97.
56. Patel MD, Joshi SD. Abnormal preprocedural international normalized ratio and platelet counts are not associated with increased bleeding complications after ultrasound-guided thoracentesis. *AJR Am J Roentgenol*. 2011;197(1):W164–W168.
57. Puchalski JT, Argento AC, Murphy TE, Araujo KLB, Pisani MA. The safety of thoracentesis in patients with uncorrected bleeding risk. *Ann Am Thorac Soc*. 2013;10(4):336–41.
58. Abdel-Wahab OI, Healy B, Dzik WH. Effect of fresh-frozen plasma transfusion on prothrombin time and bleeding in patients with mild coagulation abnormalities. *Transfusion*. 2006;46(8):1279–85.

59. Green L, Bolton-Maggs P, Beattie C, Cardigan R, Kallis Y, Stanworth SJ, et al. British Society of Haematology Guidelines on the spectrum of fresh frozen plasma and cryoprecipitate products: their handling and use in various patient groups in the absence of major bleeding (*Br J Haematol*. 2018;181:54–67). Addendum August 2020. *Br J Haematol*. 2020;191(5):728–9. <https://doi.org/10.1111/bjh.17104>
60. Mosesson MW. Fibrinogen structure and fibrin clot assembly. *Semin Thromb Hemost*. 1998;24(2):169–74.
61. Fenger-Eriksen C, Lindberg-Larsen M, Christensen AQ, Ingerslev J, Sørensen B. Fibrinogen concentrate substitution therapy in patients with massive haemorrhage and low plasma fibrinogen concentrations. *Br J Anaesth*. 2008;101(6):769–73.
62. Maegele M. The European perspective on the management of acute major hemorrhage and coagulopathy after trauma: summary of the 2019 updated European guideline. *J Clin Med*. 2021;10(2):362.
63. Oswald MW, Hunt HH, Lazarchick J. Normal range of plasma fibrinogen. *Am J Med Technol*. 1983;49(1):57–9.
64. Lowe GD, Rumley A, Woodward M, Morrison CE, Philippou H, Lane DA, et al. Epidemiology of coagulation factors, inhibitors and activation markers: the Third Glasgow MONICA Survey. I. Illustrative reference ranges by age, sex and hormone use. *Br J Haematol*. 1997;97(4):775–84.
65. Dempfle CE, Kältsch T, Elmas E, Suvajac N, Lücke T, Münch E, et al. Impact of fibrinogen concentration in severely ill patients on mechanical properties of whole blood clots. *Blood Coagul Fibrinolysis*. 2008;19(8):765–70.
66. Levy JH, Welsby I, Goodnough LT. Fibrinogen as a therapeutic target for bleeding: a review of critical levels and replacement therapy. *Transfusion*. 2014;54(5):1389–405; quiz 1388.
67. Bolliger D, Szlam F, Molinaro RJ, Rahe-Meyer N, Levy JH, Tanaka KA. Finding the optimal concentration range for fibrinogen replacement after severe haemodilution: an in vitro model. *Br J Anaesth*. 2009;102(6):793–9.
68. Roberts LN, Lisman T, Stanworth S, Hernandez-Gea V, Magnusson M, Tripodi A, et al. Periprocedural management of abnormal coagulation parameters and thrombocytopenia in patients with cirrhosis: guidance from the SSC of the ISTH. *J Thromb Haemost*. 2022;20(1):39–47.
69. Levy JH, Goodnough LT. How I use fibrinogen replacement therapy in acquired bleeding. *Blood*. 2015;125(9):1387–93.
70. Lissitchkov T, Madan B, Djambas Khayat C, Zozulya N, Ross C, Karimi M, et al. Fibrinogen concentrate for treatment of bleeding and surgical prophylaxis in congenital fibrinogen deficiency patients. *J Thromb Haemost*. 2020;18(4):815–24.
71. Josephson CD, Granger S, Assmann SF, Castillejo MI, Strauss RG, Slichter SJ, et al. Bleeding risks are higher in children versus adults given prophylactic platelet transfusions for treatment-induced hypoproliferative thrombocytopenia. *Blood*. 2012;120(4):748–60.
72. Warner MA, Woodrum D, Hanson A, Schroeder DR, Wilson G, Kor DJ. Preprocedural platelet transfusion for patients with thrombocytopenia undergoing interventional radiology procedures is not associated with reduced bleeding complications. *Transfusion*. 2017;57(4):890–8.
73. Estcourt LJ, Birchall J, Lowe D, Grant-Casey J, Rowley M, Murphy MF. Platelet transfusions in haematology patients: are we using them appropriately? *Vox Sang*. 2012;103(4):284–93.
74. van de Weert EK, Biemond BJ, Baake B, Vermin B, Binnekade JM, van Lienden KP, et al. Central venous catheter placement in coagulopathic patients: risk factors and incidence of bleeding complications. *Transfusion*. 2017;57(10):2512–25.
75. Estcourt LJ, Birchall J, Allard S, Bassey SJ, Hersey P, Kerr JP, et al. Guidelines for the use of platelet transfusions. *Br J Haematol*. 2017;176(3):365–94. <https://doi.org/10.1111/bjh.14423>
76. Hogshire LC, Patel MS, Rivera E, Carson JL. Evidence review: periprocedural use of blood products. *J Hosp Med*. 2013;8(11):647–52. <https://doi.org/10.1002/jhm.2089>
77. van Baarle FLF, van de Weert EK, van der Velden WJFM, Ruitkamp RA, Tuinman PR, Ypma PF, et al. Platelet transfusion before CVC placement in patients with thrombocytopenia. *N Engl J Med*. 2023;388(21):1956–65.
78. Bauer ME, Arendt K, Beilin Y, Gernsheimer T, Perez Botero J, James AH, et al. The Society for Obstetric Anesthesia and Perinatology Interdisciplinary Consensus Statement on neuraxial procedures in obstetric patients with thrombocytopenia. *Anesth Analg*. 2021;132(6):1531–44.
79. Working Party, Association of Anaesthetists of Great Britain & Ireland, Obstetric Anaesthetists' Association, Regional Anaesthesia UK. Regional anaesthesia and patients with abnormalities of coagulation: the Association of Anaesthetists of Great Britain & Ireland The Obstetric Anaesthetists' Association Regional Anaesthesia UK. *Anaesthesia*. 2013;68(9):966–72.
80. MacGinley R, Champion DeCrespigny PJ, Gutman T, Lopez-Vargas P, Manera K, Menahem S, et al. KHA-CARI Guideline recommendations for renal biopsy. *Nephrology*. 2019;24:1205–13. <https://doi.org/10.1111/nep.13662>
81. Burke JP, Pham T, May S, Okano S, Ratanjee SK, Thet Z, et al. Kidney biopsy practice among Australasian nephrologists. *BMC Nephrol*. 2021;22:291. <https://doi.org/10.1186/s12882-021-02505-9>
82. Nagrebetsky A, Al-Samkari H, Davis NM, Kuter DJ, Wiener-Kronish JP. Perioperative thrombocytopenia: evidence, evaluation, and emerging therapies. *Br J Anaesth*. 2019;122(1):19–31.
83. Kaufman RM, Djulbegovic B, Gernsheimer T, Kleinman S, Tinmouth AT, Capocelli KE, et al. Platelet transfusion: a clinical practice guideline from the AABB. *Ann Intern Med*. 2015;162(3):205–13.
84. van der Werf J, Porte RJ, Lisman T. Hemostasis in patients with liver disease. *Acta Gastroenterol Belg*. 2009;72(4):433–40.
85. Cosmi B, Alatri A, Cattaneo M, Gresle P, Marietta M, Rodeghiero F, et al. Assessment of the risk of bleeding in patients undergoing surgery or invasive procedures: guidelines of the Italian Society for Haemostasis and Thrombosis (SISTET). *Thromb Res*. 2009;124(5):e6–e12.
86. Lisman T, Porte RJ. Rebalanced hemostasis in patients with liver disease: evidence and clinical consequences. *Blood*. 2010;116(6):878–85.
87. Viola F, Basili S, Raparelli V, Chowdary P, Gatt A, Burroughs AK. Patients with liver cirrhosis suffer from primary haemostatic defects? Fact or fiction? *J Hepatol*. 2011;55(6):1415–27.
88. Stravitz RT, Lisman T, Luketic VA, Sterling RK, Puri P, Fuchs M, et al. Minimal effects of acute liver injury/acute liver failure on hemostasis as assessed by thromboelastography. *J Hepatol*. 2012;56(1):129–36.
89. Lisman T, Arefaïne B, Adelmeijer J, Zamalloa A, Corcoran E, Smith JG, et al. Global hemostatic status in patients with acute-on-chronic liver failure and sepsis without underlying liver disease. *J Thromb Haemost*. 2021;19(1):85–95.
90. Montalto P, Vlachogiannakos J, Cox DJ, Pastacaldi S, Patch D, Burroughs AK. Bacterial infection in cirrhosis impairs coagulation by a heparin effect: a prospective study. *J Hepatol*. 2002;37(4):463–70.
91. Drolz A, Horvatits T, Roedl K, Rutter K, Stauffer K, Kneidinger N, et al. Coagulation parameters and major bleeding in critically ill patients with cirrhosis. *Hepatology*. 2016;64(2):556–68.
92. Hung A, Garcia-Tsao G. Acute kidney injury, but not sepsis, is associated with higher procedure-related bleeding in patients with decompensated cirrhosis. *Liver Int*. 2018;38(8):1437–41.
93. DeAngelis GA, Khot R, Haskal ZJ, Maitland HS, Northup PG, Shah NL, et al. Bleeding risk and management in interventional procedures in chronic liver disease. *J Vasc Interv Radiol*. 2016;27(11):1665–74.
94. Neuberger J, Patel J, Caldwell H, Davies S, Hebditch V, Hollywood C, et al. Guidelines on the use of liver biopsy in clinical practice from the British Society of Gastroenterology, the Royal College of Radiologists and the Royal College of Pathology. *Gut*. 2020;69(8):1382–403.
95. Ewe K. Bleeding after liver biopsy does not correlate with indices of peripheral coagulation. *Dig Dis Sci*. 1981;26(5):388–93.

96. McVay PA, Toy PT. Lack of increased bleeding after liver biopsy in patients with mild hemostatic abnormalities. *Am J Clin Pathol.* 1990;94(6):747–53.
97. Caturelli E, Squillante MM, Andriulli A, Siena DA, Cellerino C, De Luca F, et al. Fine-needle liver biopsy in patients with severely impaired coagulation. *Liver.* 1993;13(5):270–3.
98. Dillon JF, Simpson KJ, Hayes PC. Liver biopsy bleeding time: an unpredictable event. *J Gastroenterol Hepatol.* 1994;9(3):269–71.
99. Boberg KM, Brosstad F, Egeland T, Egge T, Schrumpf E. Is a prolonged bleeding time associated with an increased risk of hemorrhage after liver biopsy? *Thromb Haemost.* 1999;81(3):378–81.
100. Thachil J. Relevance of clotting tests in liver disease. *Postgrad Med J.* 2008;84(990):177–81.
101. Gilmore IT, Burroughs A, Murray-Lyon IM, Williams R, Jenkins D, Hopkins A. Indications, methods, and outcomes of percutaneous liver biopsy in England and Wales: an audit by the British Society of Gastroenterology and the Royal College of Physicians of London. *Gut.* 1995;36(3):437–41.
102. Frenzel C, Koch J, Lorenzen V, Werner T, Lohse AW, Denzer UW. Complications and risk factors in 2731 diagnostic mini-laparoscopies in patients with liver disease. *Liver Int.* 2012;32(6):970–6.
103. Sandrasegaran K, Thayalan N, Thavanesan R, Kohli M, Berry W, Shah A, et al. Risk factors for bleeding after liver biopsy. *Abdom Radiol.* 2016;41(4):643–9.
104. Bissonnette J, Riescher-Tuczkiewicz A, Gigante E, Bourdin C, Boudaoud L, Soliman H, et al. Predicting bleeding after liver biopsy using comprehensive clinical and laboratory investigations: a prospective analysis of 302 procedures. *J Thromb Haemost.* 2022;20(12):2786–96.
105. Townsend JC, Heard R, Powers ER, Reuben A. Usefulness of international normalized ratio to predict bleeding complications in patients with end-stage liver disease who undergo cardiac catheterization. *Am J Cardiol.* 2012;110(7):1062–5.
106. Somani V, Amarapurkar D, Shah A. Thromboelastography for assessing the risk of bleeding in patients with cirrhosis—moving closer. *J Clin Exp Hepatol.* 2017;7(4):284–9.
107. Shah A, Amarapurkar D, Dharod M, Chandnani M, Bajjal R, Kumar P, et al. Coagulopathy in cirrhosis: a prospective study to correlate conventional tests of coagulation and bleeding following invasive procedures in cirrhotics. *Indian J Gastroenterol.* 2015;34(5):359–64.
108. Napolitano G, Iacobellis A, Merla A, Niro G, Valvano MR, Terracciano F, et al. Bleeding after invasive procedures is rare and unpredicted by platelet counts in cirrhotic patients with thrombocytopenia. *Eur J Intern Med.* 2017;38:79–82.
109. Ault MJ, Rosen BT, Scher J, Feinglass J, Barsuk JH. Thoracentesis outcomes: a 12-year experience. *Thorax.* 2015;70(2):127–32.
110. Rowley MW, Agarwal S, Seetharam AB, Hirsch KS. Real-time ultrasound-guided paracentesis by radiologists: near zero risk of hemorrhage without correction of coagulopathy. *J Vasc Interv Radiol.* 2019;30(2):259–64.
111. Intagliata NM, Rahimi RS, Higuera-de-la-Tijera F, Simonetto DA, Farias AQ, Mazo DF, et al. Procedural-Related Bleeding in Hospitalized Patients With Liver Disease (PROC-BLeED): an international, prospective, multicenter observational study. *Gastroenterology.* 2023;165(3):717–32.
112. O'Leary JG, Greenberg CS, Patton HM, Caldwell SH. AGA clinical practice update: coagulation in cirrhosis. *Gastroenterology.* 2019;157(1):34–43.e1.
113. Potte W, Porte RJ, Lisman T. Management of coagulation abnormalities in liver disease. *Expert Rev Gastroenterol Hepatol.* 2015;9(1):103–14.
114. Zimmon DS, Kessler RE. The portal pressure-blood volume relationship in cirrhosis. *Gut.* 1974;15(2):99–101.
115. Jia Q, Brown MJ, Clifford L, Wilson GA, Truty MJ, Stubbs JR, et al. Prophylactic plasma transfusion for surgical patients with abnormal preoperative coagulation tests: a single-institution propensity-adjusted cohort study. *Lancet Haematol.* 2016;3(3):e139–e148.
116. Huber J, Stanworth SJ, Doree C, Fortin PM, Trivella M, Brunskill SJ, et al. Prophylactic plasma transfusion for patients without inherited bleeding disorders or anticoagulant use undergoing non-cardiac surgery or invasive procedures. *Cochrane Database Syst Rev.* 2019;11(11):CD012745.
117. Mohanty A, Kapuria D, Canakis A, Lin H, Amat MJ, Rangel Paniz G, et al. Fresh frozen plasma transfusion in acute variceal haemorrhage: results from a multicentre cohort study. *Liver Int.* 2021;41(8):1901–8.
118. Tripodi A, Chantarangkul V, Primignani M, Clerici M, Dell'era A, Aghemo A, et al. Thrombin generation in plasma from patients with cirrhosis supplemented with normal plasma: considerations on the efficacy of treatment with fresh-frozen plasma. *Intern Emerg Med.* 2012;7(2):139–44.
119. Rassi AB, d'Amico EA, Tripodi A, da Rocha TRF, Migita BY, Ferreira CM, et al. Fresh frozen plasma transfusion in patients with cirrhosis and coagulopathy: effect on conventional coagulation tests and thrombomodulin-modified thrombin generation. *J Hepatol.* 2020;72(1):85–94.
120. von Meijenfeldt FA, van den Boom BP, Adelmeijer J, Roberts LN, Lisman T, Bernal W. Prophylactic fresh frozen plasma and platelet transfusion have a prothrombotic effect in patients with liver disease. *J Thromb Haemost.* 2021;19(3):664–76.
121. Simonetto DA, Singal AK, Garcia-Tsao G, Caldwell SH, Ahn J, Kamath PS. ACG clinical guideline: disorders of the hepatic and mesenteric circulation. *Am J Gastroenterol.* 2020;115(1):18–40.
122. Northup PG, Garcia-Pagan JC, Garcia-Tsao G, Intagliata NM, Superina RA, Roberts LN, et al. Vascular liver disorders, portal vein thrombosis, and procedural bleeding in patients with liver disease: 2020 practice guidance by the American Association for the Study of Liver Diseases. *Hepatology.* 2021;73(1):366–413.
123. O'Shea RS, Davitkov P, Ko CW, Rajasekhar A, Su GL, Sultan S, et al. AGA clinical practice guideline on the management of coagulation disorders in patients with cirrhosis. *Gastroenterology.* 2021;161(5):1615–1627.e1.
124. Smith CB, Hennessey EK, Crossey CD, Crannage AJ. Impact of vitamin K administration on elevated international normalized ratio in chronic liver disease. *Clin Appl Thromb.* 2023;29:4642.
125. Chapman AR, Yerke JR, Lumpkin M, Rudoni MA, Militello M, Wang L, et al. Evaluation of response to high-dose intravenous vitamin K administration. *Ann Pharmacother.* 2023;20:1184.
126. Stravitz RT, Kramer AH, Davern T, Shaikh AO, Caldwell SH, Mehta RL, et al. Intensive care of patients with acute liver failure: recommendations of the U.S. Acute Liver Failure Study Group. *Crit Care Med.* 2007;35(11):2498–508.
127. Latona A, Hill K, Connolly A, Stuart K, Wood P. Prothrombinex®-VF in chronic liver disease: friend or foe? *Emerg Med Australas.* 2023;35(1):89–96.
128. Seeff LB, Everson GT, Morgan TR, Curto TM, Lee WM, Ghany MG, et al. Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial. *Clin Gastroenterol Hepatol.* 2010;8(10):877–83.
129. Kitchin DR, Del Rio AM, Woods M, Ludeman L, Hinshaw JL. Percutaneous liver biopsy and revised coagulation guidelines: a 9-year experience. *Abdom Radiol.* 2018;43(6):1494–501.
130. Tripodi A, Primignani M, Chantarangkul V, Clerici M, Dell'Era A, Fabris F, et al. Thrombin generation in patients with cirrhosis: the role of platelets. *Hepatology.* 2006;44(2):440–5.
131. Afdhal NH, Giannini EG, Tayyab G, Mohsin A, Lee JW, Andriulli A, et al. Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia. *N Engl J Med.* 2012;367(8):716–24.
132. Rose PD, Au M, Woodman RJ, Tee D, Chinnaratha MA. Pre-procedural use of thrombopoietin-receptor agonists in cirrhosis and severe thrombocytopenia: a systematic review and meta-analysis. *Dig Liver Dis.* 2021;53(11):1396–403.



133. Lindquist I, Olson SR, Li A, Al-Samkari H, Jou JH, McCarty OJT, et al. The efficacy and safety of thrombopoietin receptor agonists in patients with chronic liver disease undergoing elective procedures: a systematic review and meta-analysis. *Platelets*. 2022;33(1):66–72.
134. Hall DP, Lone NI, Watson DM, Stanworth SJ, Walsh TS. Factors associated with prophylactic plasma transfusion before vascular catheterization in non-bleeding critically ill adults with prolonged prothrombin time: a case-control study. *Br J Anaesth*. 2012;109(6):919–27.
135. Chakraverty R, Davidson S, Peggs K, Stross P, Garrard C, Littlewood TJ. The incidence and cause of coagulopathies in an intensive care population. *Br J Haematol*. 1996;93(2):460–3.
136. Walsh TS, Stanworth SJ, Prescott RJ, Lee RJ, Watson DM, Wyncoll D, et al. Prevalence, management, and outcomes of critically ill patients with prothrombin time prolongation in United Kingdom intensive care units. *Crit Care Med*. 2010;38(10):1939–46.
137. Stanworth SJ, Walsh TS, Prescott RJ, Lee RJ, Watson DM, Wyncoll D, et al. A national study of plasma use in critical care: clinical indications, dose and effect on prothrombin time. *Crit Care*. 2011;15(2):R108.
138. Yaguchi A, Lobo FLM, Vincent JL, Pradier O. Platelet function in sepsis. *J Thromb Haemost*. 2004;2(12):2096–102.
139. Levi M, Opal SM. Coagulation abnormalities in critically ill patients. *Crit Care*. 2006;10(4):222.
140. Hui P, Cook DJ, Lim W, Fraser GA, Arnold DM. The frequency and clinical significance of thrombocytopenia complicating critical illness: a systematic review. *Chest*. 2011;139(2):271–8.
141. Chowdhary P, Saayman AG, Paulus U, Findlay GP, Collins PW. Efficacy of standard dose and 30 ml/kg fresh frozen plasma in correcting laboratory parameters of haemostasis in critically ill patients. *Br J Haematol*. 2004;125(1):69–73.
142. Segal JB, Dzik WH; Transfusion Medicine/Hemostasis Clinical Trials Network. Paucity of studies to support that abnormal coagulation test results predict bleeding in the setting of invasive procedures: an evidence-based review. *Transfusion*. 2005;45(9):1413–25.
143. Wheeler AP, Rice TW. Coagulopathy in critically ill patients: part 2-soluble clotting factors and hemostatic testing. *Chest*. 2010;137(1):185–94.
144. Hunt BJ. Bleeding and coagulopathies in critical care. *N Engl J Med*. 2014;370(9):847–59.
145. Levi M, Hunt BJ. A critical appraisal of point-of-care coagulation testing in critically ill patients. *J Thromb Haemost*. 2015;13(11):1960–7.
146. Müller MCA, Stanworth SJ, Coppens M, Juffermans NP. Recognition and management of hemostatic disorders in critically ill patients needing to undergo an invasive procedure. *Transfus Med Rev*. 2017;31(4):223–9.
147. Vanderschueren S, De Weerd A, Malbrain M, Vankerschaever D, Frans E, Wilmer A, et al. Thrombocytopenia and prognosis in intensive care. *Crit Care Med*. 2000;28(6):1871–6.
148. Retter A, Barrett NA. The management of abnormal haemostasis in the ICU. *Anaesthesia*. 2015;70(Suppl 1):121–7.
149. Desborough M, Stanworth S. Plasma transfusion for bedside, radiologically guided, and operating room invasive procedures. *Transfusion*. 2012;52(Suppl 1):20S–29S.
150. Müller MC, Arbous MS, Spoelstra-de Man AM, Vink R, Karakus A, Straat M, et al. Transfusion of fresh-frozen plasma in critically ill patients with a coagulopathy before invasive procedures: a randomized clinical trial (CME). *Transfusion*. 2015;55(1):26–35; quiz 25.
151. Bolton-Maggs PHB. Bullet points from SHOT: key messages and recommendations from the annual SHOT report 2013. *Transfus Med*. 2014;24(4):197–203.
152. Sarani B, Dunkman WJ, Dean L, Sonnad S, Rohrbach JJ, Gracias VH. Transfusion of fresh frozen plasma in critically ill surgical patients is associated with an increased risk of infection. *Crit Care Med*. 2008;36(4):1114–8.
153. Blood Observational Study Investigators of ANZICS-Clinical Trials Group, Westbrook A, Pettilä V, Nichol A, Bailey MJ, Syres G, et al. Transfusion practice and guidelines in Australian and New Zealand intensive care units. *Intensive Care Med*. 2010;36:1138–46.
154. Lieberman L, Bercovitz RS, Sholapur NS, Heddle NM, Stanworth SJ, Arnold DM. Platelet transfusions for critically ill patients with thrombocytopenia. *Blood*. 2014;123(8):1146–51; quiz 1280.
155. Kluge S, Meyer A, Kühnelt P, Baumann HJ, Kreymann G. Percutaneous tracheostomy is safe in patients with severe thrombocytopenia. *Chest*. 2004;126(2):547–51.
156. Baharoglu MI, Cordonnier C, Al-Shahi Salman R, de Gans K, Koopman MM, Brand A, et al. Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral haemorrhage associated with antiplatelet therapy (PATCH): a randomised, open-label, phase 3 trial. *Lancet*. 2016;387(10038):2605–13.
157. Sznajder JJ, Zveibil FR, Bitterman H, Weiner P, Bursztein S. Central vein catheterization. Failure and complication rates by three percutaneous approaches. *Arch Intern Med*. 1986;146(2):259–61.
158. Wolfe KS, Kress JP. Risk of procedural hemorrhage. *Chest*. 2016;150(1):237–46.
159. Brass P, Hellmich M, Kolodziej L, Schick G, Smith AF. Ultrasound guidance versus anatomical landmarks for internal jugular vein catheterization. *Cochrane Database Syst Rev*. 2015;1(1):CD006962.
160. Midia M, Odedra D, Shuster A, Midia R, Muir J. Predictors of bleeding complications following percutaneous image-guided liver biopsy: a scoping review. *Diagn Interv Radiol*. 2019;25(1):71–80.
161. Eiro M, Katoh T, Watanabe T. Risk factors for bleeding complications in percutaneous renal biopsy. *Clin Exp Nephrol*. 2005;9(1):40–5.
162. Shidham GB, Siddiqi N, Beres JA, Logan B, Nagaraja HN, Shidham SG, et al. Clinical risk factors associated with bleeding after native kidney biopsy. *Nephrology*. 2005;10(3):305–10.
163. Mercaldi CJ, Lanes SF. Ultrasound guidance decreases complications and improves the cost of care among patients undergoing thoracocentesis and paracentesis. *Chest*. 2013;143(2):532–8.
164. Lalu MM, Fayad A, Ahmed O, Bryson GL, Fergusson DA, Barron CC, et al. Ultrasound-guided subclavian vein catheterization: a systematic review and meta-analysis. *Crit Care Med*. 2015;43(7):1498–507.
165. Kreppel D, Antoniadis G, Seeling W. Spinal hematoma: a literature survey with meta-analysis of 613 patients. *Neurosurg Rev*. 2003;26(1):1–49.
166. Society of Thoracic Surgeons Blood Conservation Guideline Task Force, Ferraris VA, Ferraris SP, Saha SP, Hessel EA, Haan CK, et al. Perioperative blood transfusion and blood conservation in cardiac surgery: the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists clinical practice guideline. *Ann Thorac Surg*. 2007;83(5 Suppl):S27–S86.
167. Hazzi R, Mayock R. Perioperative management of hypertension. *J Xiangya Med*. 2018;3(6):4570.
168. Lim CC, Tan RY, Choo JCJ, Tan HZ, Mok I, Chin YM, et al. Estimation of risk for major bleeding in native kidney biopsies in patients with multiple risk factors. *Int Urol Nephrol*. 2022;54(2):343–8.
169. Sobolev M, Slovut DP, Lee Chang A, Shiloh AL, Eisen LA. Ultrasound-guided catheterization of the femoral artery: a systematic review and meta-analysis of randomized controlled trials. *J Invasive Cardiol*. 2015;27(7):318–23.
170. Bogabathina H, Singireddy S, Shi R, Morris L, Abdulbaki A, Zabher H, et al. Does micropuncture technique really help reduce vascular complications? *Cardiovasc revascularization med*. *Mol Interv*. 2018;19:762–5.
171. Gutzeit A, Schoch E, Reischauer C, Hergan K, Jenelten R, Binkert CA. Comparison of a 21G micropuncture needle and a regular 19G access needle for antegrade arterial access into the superficial femoral artery. *Cardiovasc Intervent Radiol*. 2014;37(2):343–7.



172. Strobel D, Bernatik T, Blank W, Will U, Reichel A, Wüstner M, et al. Incidence of bleeding in 8172 percutaneous ultrasound-guided intraabdominal diagnostic and therapeutic interventions – results of the prospective multicenter DEGUM interventional ultrasound study (PIUS study). *Ultraschall Med.* 2015;36(2):122–31.
173. Noori VJ, Eldrup-Jørgensen J. A systematic review of vascular closure devices for femoral artery puncture sites. *J Vasc Surg.* 2018;68(3):887–99.
174. Tokarek T, Dziewierz A, Plens K, Rakowski T, Zabojszcz M, Dudek D, et al. Radial approach expertise and clinical outcomes of Percutaneous coronary interventions performed using femoral approach. *J Clin Med.* 2019;8(9):1484.
175. Hulme W, Sperrin M, Rushton H, Ludman PF, De Belder M, Curzen N, et al. Is there a relationship of operator and center volume with access site-related outcomes? *Circ Cardiovasc Interv.* 2016;9(5):e003333.
176. Mueller M, Kratzer W, Oeztuerk S, Wilhelm M, Mason RA, Mao R, et al. Percutaneous ultrasonographically guided liver punctures: an analysis of 1961 patients over a period of ten years. *BMC Gastroenterol.* 2012;5:173.

**How to cite this article:** Lester W, Bent C, Alikhan R, Roberts L, Gordon-Walker T, Trenfield S, et al. A British Society for Haematology guideline on the assessment and management of bleeding risk prior to invasive procedures. *Br J Haematol.* 2024;204(5):1697–1713. <https://doi.org/10.1111/bjh.19360>

## APPENDIX

### METHODOLOGY

MEDLINE (OVID) 1946 to 3 May 2023

EMBASE (OVID) 1974 to 2019 week 18

CENTRAL (Cochrane Central Register of Controlled Trials)

Main keywords used (alternative spellings/related terms also searched) and search structure:

surgical procedures; operative; surgery; surgical; invasive procedure; interventional radiology; biopsy; percutaneous AND

blood coagulation disorders; blood coagulation tests; hematologic tests; bleeding time; prothrombin time; partial thromboplastin time; international normalised ratio; APTT; PT; PTT; INR; bleeding risk assessment; coagulopathy; PFA-100; thromboelastogram; ROTEM; bleeding history; bleeding questionnaire AND

surgical blood loss; blood transfusion; postoperative haemorrhage/bleed; post-intervention haemorrhage/bleed; post-biopsy haemorrhage/bleed; post-procedure haemorrhage/bleed incidence AND

vitamin K; prevalence AND

vitamin K; vitamin K deficiency; hypovitaminosis K; PIVKA